US 12,138,253 B2
Tumor suppression
Masatoshi Hagiwara, Kyoto (JP); Masahiko Ajiro, Kyoto (JP); and Tetsunori Sakamoto, Kyoto (JP)
Assigned to KYOTO UNIVERSITY, Kyoto (JP)
Filed by Kyoto University, Kyoto (JP)
Filed on Sep. 17, 2020, as Appl. No. 17/024,435.
Claims priority of application No. 2019-168668 (JP), filed on Sep. 17, 2019.
Prior Publication US 2021/0100781 A1, Apr. 8, 2021
Int. Cl. A61K 31/4409 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4409 (2013.01) [A61P 35/00 (2018.01)] 11 Claims
 
1. A method for ameliorating, suppressing progression of, and/or treating a tumor caused by a tumor virus, the method comprising the step of:
administering, to a subject having the tumor, an effective amount of a component that targets a gene product of the tumor virus;
wherein the tumor virus is Kaposi sarcoma-associated herpesvirus (KSHV),
wherein the tumor caused by a tumor virus is at least one of Kaposi sarcoma or a KSHV-associated tumor, and
wherein the component that targets the gene product of the tumor virus is a compound expressed as Formula (II) below, or a pharmaceutically acceptable salt of the compound:

OG Complex Work Unit Chemistry
 wherein
R4 represents a hydrogen atom; a halogen atom; a substituted or unsubstituted C1-6 alkyl group; a substituted or unsubstituted C2-6 alkenyl group; a substituted or unsubstituted C2-6 alkynyl group; or a substituted or unsubstituted aryl group,
R5 represents a hydrogen atom; a halogen atom; an amino group; or an azide group,
R7 represents a hydrogen atom; a halogen atom; a diethylamino group; a substituted or unsubstituted nitrogen-containing heterocycloalkyl group; or a substituted or unsubstituted nitrogen-containing heteroaryl group,
R8 represents an oxygen atom or a sulfur atom, and
R9 represents a hydrogen atom; a C1-6 alkyl group; or a C2-6 alkynyl group.